Veracyte, Inc. Overview
VCYT market data
Price HistoryDaily closing bars from the ranked market-data provider chain, not a live tape. The most recent bar is the last completed session, so it lags an open market.
VCYT price chart · 1M
- O
- 50.44
- H
- 51.57
- L
- 50.44
- C
- 51.57
- Vol
- 3,812.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $50.44
- Previous Close
- $50.42
- Day High
- $51.57
- Day Low
- $50.44
- 52 Week High
- $60.77
- 52 Week Low
- $29.46
- 7 Day Return
- +11.50%
- 30 Day Return
- +14.00%
- 90 Day Return
- -13.80%
- 1 Year Return
- +44.84%
- Daily Notional Volume
- $196.6K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- 33.78 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.82 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.99 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 20.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $29.46 – $60.91 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.9B · P/B 2.54 · P/S 6.88.
Company NewsSymbol-tagged NewsEvent via getLatestNewsEventsBySymbol (Prisma first, Redis news:latest:v2 fallback). Operator cap 12 / public 10; low-signal filtered, headlines deduped. Display-only—scored signals stay on the separate signals surface.
10 captured
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerGlobenewswire Inc ·
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YZacks Investment Research ·
Reasons to Hold Veeva Systems Stock in Your Portfolio for NowZacks Investment Research ·
Is it the Right Time to Add Phibro Stock to Your Portfolio?Zacks Investment Research ·
Smith+Nephew Launches CARTIHEAL Implant Across Key European MarketsZacks Investment Research ·
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma CareZacks Investment Research ·